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Abstract
Purpose: This work investigated the delivery accuracy of high-dose lung and spine stereotactic
treatments delivered with the Elekta Infinity and Versa HD platforms. The accuracy of these platforms will
be used for consideration in implementing a spine stereotactic radiosurgery (SSRS) program at Mary Bird
Perkins Cancer Center.
Methods: A geometric phantom was used to perform Winston-Lutz type tests that assessed the relevant
degrees of freedom (gantry, collimator, and couch) of the delivery system. A lung stereotactic body
radiation therapy (SBRT) and spine SRS treatment plan were generated for use in end-to-end testing.
Delivery accuracy was tested using a novel diode array design, which achieved a spatial resolution of 1
mm along a single axis. On board imaging aided in setup of the diode array to the desired position before
commencing treatment delivery. The delivered dose distribution and calculated planar dose distributions
were compared and analyzed. Several metrics were analyzed from the overlaid profiles, including:
percent difference between calculated and measured field centers, and comparison of spatial shifts of the
75% and 60% isodose levels. Percent difference between a calculated and measured point dose
quantified discrepancies for the approximate region of the spinal cord. Calculated dose profiles and shifts
at the 60 and 75% isodose levels indicated distortions in the profiles.
Results: All machines demonstrated an MV Isocenter radius for gantry and treatment table rotation less
than 0.70 mm as limited by the Elekta customer acceptance protocol. For SSRS plans, percent difference
of the point representing the spinal cord produced results that were consistently higher as a result of a
higher dose delivery than calculated. All lung SBRT and SSRS deliveries were capable of achieving an
average of 1-mm accuracy. Moreover, profiles showed that the measured profile fell within the planned
profile, suggesting a systematic distortion in the profiles.
Conclusion: Based on the findings of this project, the Elekta Infinity and Versa HD delivery systems were
adequate for lung SBRT treatments but require further exploration for the commencement of spine SRS
treatments at Mary Bird Perkins Cancer Center.
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Chapter 1. Introduction
1.1 Background and Significance
1.1.1 Stereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy (SBRT) is a non-invasive cancer treatment where high
doses of external beam radiation are delivered in a limited number of fractions to extra-cranial sites.
SBRT derived from stereotactic radiosurgery (SRS), which was originally used to treat intracranial and
spinal tumors as well as other disorders of the brain with the use of body frames and three- dimensional
imaging to localize lesions (Khan, 2010). Since the advent of on-board imaging, SBRT has become a
feasible treatment options since body frames are not required for treatments. Systems now utilize x-ray
imaging of bony anatomy and implanted fiducial marker to localize the target (Khan, 2010). Reductions in
errors and uncertainties in patient positioning and targeting have been made possible due to image
guided radiation therapy (IGRT) (Court et al., 2008). IGRT has provided new capabilities of treatment that
have increased dose delivery precision to the target and avoidance of organs at risk (OAR). This is
achievable since image guidance can be utilized before, during, or after any radiation therapy treatment.
Implementation of beam shaping and image guidance technology have enhanced the performance of
SBRT in reducing safety margins and precisely conforming to the tumor outline in all three dimensions
(Greco et al., 2015). The additional confidence that IGRT provides for patient positioning has been crucial
in implementing innovative treatments to ablate tumors, such as with stereotactic body radiation therapy
(Greco et al., 2015).
A typical SBRT plan will vary from a conventional radiotherapy plan in several ways. SBRT plans employ
1 to 5 fractions with doses ranging from 6 to 30 Gy per fraction, whereas conventional treatments use
anywhere from 10 to 30 treatments with doses ranging from 1.8 to 3Gy per fraction (Benedict et al.,
2010). Typically those treatments with only one treatment fraction are termed stereotactic radiosurgery
because of its similar outcome to surgery without invasive means. Target definition also varies for the two
treatment plans. Conventional radiotherapy treatments will treat tumors that may not have sharp
boundaries, which are accounted for with margins on the order of centimeters, whereas SBRT treatments
require tumors to be well defined with any additional margins on the order of millimeters due to the high,
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conformal dose of the target volume (Benedict et al., 2010). Targeting and conformity requirements are
higher for SBRT and SRS treatments because of the larger doses delivered in fewer fractions, meaning
that inaccurate targeting will have a greater effect on normal tissues with stereotactic treatments. Also,
SBRT treatments typically employ more beams than conventional treatments in order to achieve this
degree of conformality. In addition to the number of beams, delivery techniques such as noncoplanar
beam arrangements, inhomogeneous dose distributions, and IMRT are often used for SBRT treatments in
order to minimize the dose to surrounding normal tissue (Benedict et al., 2010).
Whereas conventional radiotherapy delivers a prescribed dose to large volumes over many small-dose
fractions spanning months, SBRT delivers the prescription dose to smaller target volumes via
hypofractionation (Benedict et al., 2010). Hypofractionation utilizes a higher dose per fraction to increase
the biologically effective dose (BED), which is used to evaluate the effects of different fractionation
schedules because it varies according to dose per fraction, number of fractions, and tissue
characteristics. In order for the objective of ablative radiation therapy to be met, as opposed to regional
adjuvant therapy for cancers such as rectum, breast, and sarcoma that have been treated by other
means such as surgery and chemotherapy, the dose prescription must radically change by increasing the
dose and decreasing the number of fractions (Papiez and Timmerman, 2008). The result is an ablative
dose per fraction where damage to adjacent critical structures is avoided by maintaining a sharp dose falloff around the target (Amini et al., 2014). When effects of equivalent total doses with different
fractionation regimens are compared, they produce unequal biological effects (Kong et al., 2014).
Achieving a high BED has been shown to increase overall survival by improving tumor control rate for
non-small cell lung cancer, paraspinal and spinal metastasis, and oligometastastic liver disease (Kong et
al., 2014; Zhang et al., 2011; Sheehan and Jagannathan, 2008; Berkovic et al., 2017). Due to the ablative
nature of SBRT, this hypofractionated approach more closely follows the model of surgery than
conventional radiotherapy. This makes SBRT an attractive option for patients unwilling or incapable of
undergoing surgery (Papiez and Timmerman, 2008). Specifically, SBRT has been proven highly effective
for controlling specific cancers of the thorax, abdomen, and spine (Benedict et al., 2010; Nalichowski et
al., 2017).
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1.1.2 Lung Cancer
As shown in Figure 1.1, lung cancer is estimated to be the second cancer in terms of incidence
and the leading cause of cancer death within the United States, accounting for approximately 25% of
estimated deaths for both men and women (American Cancer Society, 2018). In order to treat this
prevalent cancer, primary tumor control becomes the essential requirement for the treatment of lung
cancer (Timmerman et al., 2010). Long-term follow up of patients treated with conventional fractionation
techniques for non-small cell lung cancer showed that only 20-30% of these tumors stopped growth or
recessed (Papiez and Timmerman, 2008). Moreover, it has been shown that patients with early stage,
medically inoperable lung cancer have low primary tumor control rates of approximately 30-40%
(Timmerman et al., 2010). According to Timmerman et al.’s findings, SBRT delivered according Radiation
Therapy Oncology Group Report 0236 to early stage lung cancer patients provided more than double the
rate of primary tumor control than reports describing conventional radiotherapy.

Figure 1.1. 2018 Estimates for Leading Sites of New Cancer Cases and Deaths in the United States
(American Cancer Society, 2018).
It is believed that the hypofractionated doses in SBRT contribute to an improved local control via
clonogenic cell death from DNA strand breaks, chromosome aberrations, and vascular damage in tumors
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that lead to indirect cell death (Song et al., 2013). Since SBRT delivers a much higher BED than
conventional therapy, it has been shown to lead to long survival and local tumor control for patients with
non-small cell lung cancer (Kong et al., 2014).

1.1.3 Spinal Metastases
It is estimated that approximately 10% of cancer patients will develop vertebral or spinal
metastases, typically originating from primary breast, lung, prostate, and renal cell carcinomas (Greco et
al., 2015). This type of metastasis can affect a patient’s stability and neurologic function, therefore the
two primary therapeutic targets of single dose SBRT for spinal metastases are pain control and spine
stabilization in order to avoid cord compression (Greco et al., 2015). Deterioration of the vertebral column
as a result of spinal metastasis is shown in Figure 1.2. SBRT is a non-invasive treatment option for
patients unwilling to undergo surgery, with gross residual disease or deemed high risk for recurrence
post-surgery, and for those with a poor performance status (Sahgal et al.). SBRT allows for escalation of
tumor dose while also sparing adjacent organs at risk, particularly the spinal cord, making it an attractive
alternative to surgery for patients with spinal metastases. Moreover, it has been reported that 86% of
patients experienced long-term pain improvement and excellent local control with SBRT (Nalichowski et
al., 2017). Overall, radiation therapy has primarily been used for palliative management of spinal
metastases in patients unwilling or unfit for surgery.

Figure 1.2. Axial computed tomographic view of a patient with spinal metastasis. The diseased T12
vertebra is contoured in red.

4

1.2 Motivation for Research
Due to the numerous people affected by lung cancer and the challenge its location in a non-rigid
structure presents, high levels of precision must be obtained in order to achieve a curative treatment.
Specifically, 2-mm accuracy falls within the range of achievable setup accuracies for lung SBRT
treatments utilizing various immobilization devices (Benedict et al., 2010; Nagata et al., 2002; Hara et al.,
2002; Wulf et al., 2000; Hof et al., 2003; Wang et al., 2006) with a 1-mm accuracy proven to be
achievable for end-to-end localization accuracy including setup uncertainty but withholding intrafraction
errors (Solberg et al., 2008; Verellen et al., 2003; Sharpe et al., 2006). 1-mm accuracy is generally
recommended for spine SBRT cases considering the dosimetric effect to the spinal cord of translational
errors greater than 1 mm (Guckenberger et al., 2007; Wang et al., 2008). Moreover, 1-mm accuracy has
been achieved for setup with the use of stereotactic body frames (Guckenberger et al., 2007; Wang et al.,
2008; Chang et al., 2004; Yenice et al., 2003; Lohr et al., 1999) as well as end-to-end localization (Ryu et
al., 2001; Yu et al., 2004). Additionally, with the spine as the most common site of bone metastases, their
management poses a challenge in clinical oncology due to larger treatment volumes, numerous organs at
risk, and lack of rigid, frame-based immobilization (Katagiri et al., 1998; Sheehan and Jagannathan,
2008).
The large doses per fraction in SBRT lead to tumor ablation. However, healthy tissue cells can be
critically damaged if they are exposed to these high levels of radiation (Papiez and Timmerman, 2008).
Therefore, SBRT requires a high degree of accuracy. This is achieved throughout the treatment process
with the use of immobilization devices, simulation, treatment planning, and on-board imaging. Overall,
accurate dose delivery is dependent on correct patient positioning and physical delivery of the planned
dose. There are uncertainties that one encounters during the treatment process; for example,
uncertainties resulting from the imaging system used in simulation and patient positioning verification,
mechanical uncertainties in positioning (such as the treatment couch position), and dose delivery
uncertainties. The latter are related to the linear accelerator output and its mechanical uncertainties in
delivery such as gantry positioning and multi-leaf collimator positioning.
This research focuses on these types of uncertainties as they apply to the Elekta Infinity linear
accelerator equipped with an Agility head, as shown in Figure 1.3, as well as the Versa HD
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accelerator (Elekta, Stockholm, Sweden). The evaluation of these linear accelerators for their continued
use in lung stereotactic body radiotherapy and their initial use in spinal stereotactic radiosurgery (SSRS)
at Mary Bird Perkins Cancer Center (MBPCC) serves as the motivation for this project.

Figure 1.3. Mary Bird Perkins Cancer Center Elekta Infinity linear accelerator with Agility head. MV-CBCT
and orthogonal kV-CBCT onboard imaging pictured.

1.3 Hypothesis and Specific Aims
The hypothesis of this work is that the Elekta Infinity and Versa HD platforms will be sufficient for
lung SBRT and spine SRS treatments as deemed by clinical standards and metrics including percent
difference between measured and calculated doses, positional alignment, and shifts in isodose levels that
were designed for this project. The specific aims formulated to address the hypothesis of this work are:
Aim 1: Generate a lung SBRT treatment plan following RTOG 0813 protocol and a spine SRS treatment
plan following RTOG 0631 protocol.
Aim 2: Measure delivery accuracy through geometric and end-to-end testing.
Sub-Aim 2a: Perform Winston-Lutz type test to assess MV isocenter accuracy.
Sub-Aim 2b: Deliver treatment plans using a diode array phantom with 1-millimeter resolution.
Aim 3: Evaluate delivery accuracy of the Elekta Infinity with Agility Head and Versa HD platforms.

6

Chapter 2. Methods and Materials
2.1 Aim 1
To assess the delivery accuracy of the Elekta linear accelerators, treatment plans were
developed so that their delivery could be evaluated on multiple platforms. In Aim 1, two treatment plans
3

were created using the Pinnacle treatment planning system (Philips Radiation Oncology Systems,
Fitchburg, WI). A 3D conformal treatment plan was generated for a lung SBRT case and a static MLC
(sMLC) IMRT treatment plan was created for a spine SRS case.

2.1.1 Lung SBRT Treatment Plan
A single patient with a right lung tumor was selected and anonymized for this study. The patient
was previously treated with SBRT to a prescription of 50 Gy over 5 fractions using a volumetric modulate
arc therapy (VMAT) technique. Since the goal of this study was to assess the delivery accuracy of the
system as a whole, highly modulated or dynamically modulated plans increase complexity and introduce
additional uncertainties attributable to the MLC model in the TPS. Therefore, a 3D conformal treatment
plan was created to reduce TPS model uncertainties (Sutton et al., 2014). The Radiation Therapy
Oncology Group (RTOG) Report 0813 protocol was followed to generate the treatment plan. Per the
protocol, a 9-field 3D conformal lung stereotactic body radiotherapy plan was created consisting of seven
static coplanar beams with the couch at 0 degrees and gantry angles of 0, 40, 135, 180, 220, 265, and
310 degrees; and two noncoplanar beams with the couch placed at 45 degrees and gantry placed at 315
degrees and conversely, with the couch placed at 315 degrees and gantry placed at 45 degrees (Figure
2.1). Seven of the nine beams were planned at 6 megavoltage (MV) photon energy, with the remaining
two beams planned at 10 MV photon energy. Two 6 MV beams were changed to 10 MV beams in order
to minimize a few small hot spots. Gantry angles were chosen to avoid dose to normal tissue, which is of
particular concern in SBRT cases that employ high doses per fraction. The chosen gantry beam formation
permitted for tolerable doses to two prominent OARS for this case: the great vessels and the contralateral
lung.
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Figure 2.1. Transaxial view of the 7-coplanar and 2-noncoplanar-beam (not pictured) treatment plan for
the lung SBRT patient. The PTV is contoured pink in this image plane.
The internal target volume (ITV), which includes the gross tumor volume (GTV) and accounts for
respiratory motion, planning target volume (PTV), and additional contours were generated by a radiation
oncologist. The PTV is defined by the International Committee on Radiation Units and Measurements
(ICRU) Report 62 as the target volume necessary to account for external treatment inaccuracies including
those resulting from patient positioning, mechanical uncertainties of the equipment, and dosimetric
uncertainties (Wambersie, 1999). Field aperture size and shape conformed to the projection of the PTV
along the beam’s eye view for each beam, therefore no additional margin was added to the edge of the
blocks or MLC jaws beyond the PTV. This approach followed RTOG 0813 protocol. Beams at gantry
angles of 40 and135° with the treatment table at 0° as well as the two non-coplanar beams at gantry
angles of 45 and 315° with treatment table angles of 315° and 45°, respectively, were weighted
approximately 14% due to the shorter path they traversed through normal tissue. Conversely, the
remaining oblique beams were given approximately half this weight. The remaining beam of 265° was
weighted approximately 12%, even though it was traversing the most amount of normal tissue, in order to
offset those beams approaching from the contralateral side. The isocenter corresponded to the center of
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the mass and the plan was normalized to this point by approximately 67% so that the prescription dose
would be delivered to the margin of the PTV. In addition to the beam parameters, the dose grid resolution
was set to 1mm when calculating the projected dose calculation. Isodose plots for the lung SBRT
treatment plan are shown in Figure 2.2.

Figure 2.2. Isodose plot of the lung SBRT treatment plan in the axial (top center), sagittal (bottom left) and
coronal (bottom right) planes. The PTV is highlighted in red.

2.1.2 SSRS Treatment Plan
A patient previously treated for a spine metastasis of the T-12 vertebra was anonymized for this
study. The gross tumor volume (GTV) and clinical target volume (CTV) were contoured by a radiation
oncologist. Per ICRU Report 62, the gross tumor volume is defined as the visible extent and location of
the malignant growth with the CTV containing the GTV as well as an expansion for any subclinical
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microscopic disease that is not visible by diagnostic means (Wambersie, 1999). For this treatment plan,
the CTV was contoured to include the entire vertebral body. The GTV prescription was set to 24 Gy and
the CTV prescription was set to 16 Gy for a single fraction. These doses were specified as objectives in
the form of a minimum of 95% coverage in the inverse planning module of the Pinnacle treatment
planning system. Per protocol, a treatment plan is acceptable as long as >90% of the target volume
receives the prescribed radiosurgery dose. A step and shoot IMRT plan was created according to RTOG
Report 0631, since the use of IMRT could not be avoided for a plan with the target volume directly
adjacent to the spinal cord. With the patient supine, 9 posterior 6 MV photon beams were generated with
20 degrees of separation spanning from 260 to 100 degrees (Figure 2.3). Other objectives included
maximum doses to the stomach, liver, kidneys, and bowel that were not to exceed their tolerance (to be
described in Section 3.1.2) as defined by RTOG Report 0631 and MBPCC. The highest weight of the
objectives was assigned to those pertaining to the GTV and CTV. The plan was initially optimized to 75
iterations, with 25 iterations for the opening density matrix via pencil beam. A “warm start” of 50 iterations
followed, and finally 30 further iterations were used to achieve a composite objective value of 0.11, which
is satisfactory for this type of plan. The dose grid resolution was set to 1mm. The isodose plot of the
treatment plan is shown in Figure 2.4. Per RTOG Report 0631, the clinical target volume included the
involved vertebral body as well as both left and right pedicles.

Figure 2.3. Transaxial view of the 9-beam treatment plan for the vertebral CTV contoured in pink and the
spinal cord (OAR) is highlighted in yellow.
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Figure 2.4. Isodose plot of the spine SRS treatment plan in all three planes. The PTV is highlighted in
pink and the spinal cord (OAR) is highlighted in yellow.

2.1.3 Planar Dose Export
Plans were copied to an image set of the MapCHECK2 phantom with MapPHAN in order to
generate planar dose files which were used for comparison to delivered treatment plans. Density
3

3

3

overrides of 1.05 g/cm , 1.5027 g/cm , and 1.6667 g/cm were performed to account for the MapPHAN,
bottom section, and top section of the MapCHECK2, respectively. The planar dose tool in Pinnacle
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v9.10 was used to generate and export an ASCII planar dose file for each plan. The 2D coronal dose
plane through isocenter of the spine SRS and lung SBRT plans, as well as the posterior points of 2.0 cm
and 2.7 cm for the SSRS plan (see Section 2.2.2), were exported from the TPS 3D dose matrix for each
2

treatment plan. Planar doses were calculated for a 13×13cm square field with a resolution of 1mm.
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2.2 Aim 2
The targeting accuracy of the Elekta with an Agility head (Elekta, Stockholm, Sweden, one
located at Mary Bird Perkins Cancer Center in Baton Rouge, Serial Number: 151892 and one located at
the MBPCC Gonzales site, Serial Number: 151785) linear accelerator system as well as the Elekta Versa
HD

TM

linear accelerator system (located at the MBPCC Baton Rouge site, Serial Number: 153187) were

tested through geometric testing in the form of a Winston-Lutz type test and end-to-end testing in which
the plans from Aim 1 were delivered. Moreover, the reproducibility of the experimental set up was also
evaluated in this aim.

2.2.1 MV Isocenter Accuracy Test
In order to test the mechanical component of targeting accuracy for the Elekta linear accelerator,
geometric testing was performed with a vendor-supplied Winston-Lutz type test (called the MV Isocenter
Accuracy Test in this work), which followed the vendor-supplied protocol for Customer Acceptance Tests
for MV Isocenter Accuracy. Following the stated workflow (Clements, 2016), the steps for the WinstonLutz test were as follows:
1. A small high-density (typically tungsten or steel) ball bearing (BB) is placed at a location in the
treatment room that is defined to be the mechanical isocenter point. This definition can refer to:
coincidence of room lasers, coincidence of light-field crosshairs, or location of the tip of a frontpointer device. Typically, the BB is placed on the treatment table such that it rotates and
translates with the table.
2. A small radiation field is projected through the BB onto an image receptor, such as film or
electronic portal imaging device (EPID), using an aperture defined by MLC, primary collimator
(jaws), or stereotactic cone.
3. Projection images of the above are acquired for various gantry rotations and table rotations.
Generally a total of eight images are acquired at varying gantry and couch angles in order to
encompass the largest range of motion during a stereotactic treatment.
4. For each projection image, the 2D deviation between the center of the BB and the center of the
radiation field is found.
For the purposes of this research, the geometric phantom consisted of the kV x-ray volume imaging (XVI)
ball-bearing (BB) phantom (Elekta, Stockholm, Sweden) made of steel with a diameter of 8mm. The steel
ball is located at the tip of a plastic tube that is connected to a plate, which attaches to the treatment table
so that the BB is suspended off the table. The base plate is equipped with a set of vernier adjustments
that allow the position of the BB to be adjusted by 0.01 mm increments. A circular collimator of 50-mm
diameter was attached to the treatment head. The service cone was equipped with a set of micrometers
to adjust the position of the stereotactic collimator. The gantry was set at 0° to verify the cone was
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centered with respect to the central axis and the BB was aligned to the room crosshairs. EPID images
were acquired with the collimator at 0° and 180°. A 6MV energy beam was used to collect all images for
the MV Isocenter Accuracy Test. Adjustments to the micrometers were made until there was no apparent
movement between the images and the difference in pixel position was zero (Figure 2.5). This step
verified that the cone alignment remained the same for varying angles, therefore the collimator was left at
0° for subsequent image acquisitions.

Figure 2.5. Comparison of the longitudinal (1) or lateral (2) edge of EPID images of the collimator
aperture collected at collimator angles of 0° and 180° with the gantry placed at 0°. Adjustments to the
collimator micrometers were made until the pixel value for the edge of the field were the same.
The position of the ball-bearing phantom was set by acquiring four EPID images of the phantom
at the cardinal gantry angles using the iViewGT system (Elekta, Stockholm, Sweden). These images
were then analyzed using commercial analysis software (RIT Isocenter Analysis Tool software V.6.3.1,
Radiological Imagining Technology, Colorado Springs, CO) as recommended by the protocol of the
vendor-supplied MV Isocenter Accuracy Test. The software calculated the systemic displacement on
each principal axis using the method described in Low’s paper on minimization of target localization error
in accelerator based radiosurgery (Low et al., 1995). Adjustments were made to the three micrometers on
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the phantom based on the deviation results from the software analysis. Images at the four cardinal angles
were re-acquired until the deviation between the MV isocenter and center of the ball-bearing phantom
were less than or equal to the isocenter position tolerance of 0.1 mm. Four additional images were
acquired with treatment table isocentric rotation angles of -90°, -45°, 45°, and 90°. The projections and
standard deviation of the field-ball offset for each of the principal axes for were then calculated from the
set of eight images using the analysis software.

2.2.2 Diode Array Measurements
In order to test the therapeutic delivery accuracy of the Elekta linear accelerator, a twodimensional diode array (MapCHECK2 serial number: 76352038; Sun Nuclear Corporation, Melbourne,
FL) was selected as the dosimeter to measure delivered dose because of its detector sensitivity. The 2D
2

diode array contained 1527 diodes and an active detector area of 0.64 mm spanning a field size of 32.0
× 26.0 cm. A distance of 10.0 mm separates the diodes horizontally and vertically with a spacing of 7.1
mm diagonally.
As previously mentioned (Section 2.1.3), treatment plans were copied to a CT scan of the diode
array so that calculated dose values could be compared to delivered doses for assessment of end-to-end
testing. Due to the calibration limitations of the array, in which only one photon energy can be used for
calibration before a measurement session, the lung SBRT treatment plan was adjusted so that the plan
only utilized 6 MV photon beams rather than a combination of 6MV and 10MV photon beam energies.
This enabled the correct calibration dose to be applied to the collection of one plan with the same energy
for each beam. Calibrations were performed before each measurement session. The diode array was
also limited in its spatial resolution, with diodes spaced 1 cm apart along the horizontal and vertical axis of
the device. For the purposes of this project, we required a resolution of 1 mm in order to assess the
delivery accuracy of high dose to small target volumes. To achieve 1-mm resolution, the A40 Series
UniSlide stage (Velmex, Inc. Bloomfield, NY) was employed that allowed for incremental shifts to the
diode array using an aluminum, vernier scale-controlled stage that moved in one direction. According to
the manufacturer, the stage had a repeatability of 4 microns with straight-line accuracy of 0.076mm.
Planar dose distributions of each treatment plan were measured using the diode array as shown
in Figures 2.6, 2.7, 2.8, and 2.9. The electronic section of the diode array was centered over the moving
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stage of the stepper motor and weighed down with steel weights so that the active detective area was
suspended over the end of the treatment table. This configuration was used to prevent any treatment
beams from passing through the aluminum apparatus of the electronic portion of the array. The solid
water enclosure (MapPHAN, Sun Nuclear Corporation, Melbourne, FL) that is often used in combination
with the diode array was not used for this study due to the additional weight it would have introduced.

Figure 2.6. Patient left lateral view of x-axis (coronal right/left) shifting mechanism.

Figure 2.7. Patient right lateral view of x-axis (coronal right/left) shifting mechanism.
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Figure 2.8. Patient right lateral view of the setup for y-axis (coronal inferior/superior) shifting mechanism.

Figure 2.9. Beam’s eye view for the setup for y-axis (coronal inferior/superior) shifting mechanism.
All measurements of the lung SBRT and spine SRS plans were taken in the coronal plane. For
those deliveries in which the diode array was positioned at isocenter, shifts were made along the x-axis
and y-axis, defined as patient left and patient right; and patient superior and inferior, respectively. These
measurements are referred to as coronal left/right and coronal superior/inferior in this work. In addition to
the plane through the isocenter for the SSRS case, two supplementary coronal planes were evaluated in
the posterior direction of the patient (i.e. the diode array was shifted vertically down). These additional
positions represent the coronal plane along the z-axis for the SSRS case. Since the array orientation was
in the coronal plane, shifts along the x-axis using the aluminum stage were performed in order to assess
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the dose delivery to the steepest dose gradients in the plan. These areas are characterized by the
horseshoe shape isodose lines encompassing the vertebral column and excluding the spinal cord so that
dose can be limited to the spinal cord. One of the coronal posterior positions was taken at 2 cm and the
other at 2.7 cm (Figure 2.10). These points were chosen to represent the coronal plane approximately
through the juncture of the vertebral PTV and spinal cord contour (a high dose gradient region) and the
coronal plane directly through the spinal cord and adjacent vertebral pedicles, respectively (Figures 2.11
and 2.12).

Figure 2.10. SSRS plan with 2cm and 2.7cm distance measured from CTV isocenter displayed in the
axial plane with corresponding sagittal (bottom left) and coronal (bottom right) planes displayed. The CTV
is outlined in red and the OAR (spinal cord) is contoured in yellow.

Figure 2.11. SSRS coronal plane of 2 cm posterior shift from CTV isocenter. The OAR (spinal cord) is
contoured in yellow with the 16 Gy isodose line targeting the CTV outlined in blue and the 24 Gy isodose
line targeting the GTV in green.
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Figure 2.12. SSRS coronal plane of 2.7 cm posterior shift from CTV isocenter. The OAR (spinal cord) is
contoured in yellow with the 16 Gy isodose line targeting the CTV outlined in blue and the 24 Gy isodose
line targeting the GTV in green.

2.2.3 Diode Array Positioning with kV-CBCT
These additional vertically positioned measurements were also designed to test the IGRT
capabilities of the Elekta Infinity platform. For those measurements of the lung SBRT and spine SRS plan
taken through the isocentric coronal plane, the diode array was aligned using the room lasers so that the
plane of diodes was parallel to the coronal plane of a supine patient. Rather than moving the treatment
table to the desired posterior offset for the spine SRS plan by referencing the monitor readouts with 0.1
cm precision, IGRT capabilities provided images before and after posterior positioning that allowed for
comparison and confirmation of the applied alignment with 0.01 cm precision. To position the
MapCHECK2 to its specified positions of 2 cm and 2.7 cm posteriorly, a kilovoltage cone beam computed
tomography (kV-CBCT) image was taken using the x-ray volume imaging system (XVI) to align the diode
array position with that in the planning CT data set of the phantom exported from the TPS. Each kVCBCT was acquired using the “S20 Head and Neck” MBPCC protocol where a cone-beam is taken
without a filter (F0) using a small collimator field of view with an axial length of 26 cm (S20). The protocol
uses a small field-of-view, kV tube potential of 100kV, and current of 10 mA. Once the kV-CBCT was
acquired, it was automatically registered to the reference CT image set using grey-scale matching (Figure
2.13). A clipbox was set to only include the central diodes of the array so as to avoid any misalignment
due to image artifacts from the outer edges of the kV-CBCT. However, the perimeter of the diode array,
as seen in the coronal image window in Figure 2.13 and 2.14, was used to confirm that the row alignment
of the diodes was correct. The registration was visually evaluated using a dual-image system that
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overlays the images. After the diode array was aligned to the reference image, the table was then
positioned the calculated amount and a kV-CBCT was re-acquired in order to ensure the adjusted
position was within ±0.05 cm of what was expected (Figure 2.14). For the spine SRS treatment plan only,
the posterior offset was achieved once the Elekta Infinity software automatically translated the treatment
table by the specified amounts. The SSRS plan was then delivered to the diode array after the desired
posterior position was achieved.

Figure 2.13. Screenshot of XVI 3D-kVCBCT registration window. The kVCBCT was aligned to the
planning CT at isocenter in this figure. (Cross sections represent the overlaid intersection of the acquired
CBCT, shown here as the lighter contrasted image, and the Pinnacle Export reference image, shown
here as the darker contrasted image).

Figure 2.14. Screenshot of XVI 3D-kVCBCT registration window. The kVCBCT was aligned to the
planning CT at isocenter in this figure after a 2cm posterior shift. (Cross sections represent the overlaid
intersection of the acquired CBCT, shown here as the lighter contrasted image, and the Pinnacle Export
reference image, shown here as the darker contrasted image).
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2.2.4 Concatenation of Measurements
An in-house MATLAB (MathWorks Inc., Natick, Massachusetts) code was developed to
concatenate the 1-mm shifted data into one file to be analyzed by the commercial software that supports
the diode array (SNC Patient
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software, version 6.2.2, Sun Nuclear Corporation, Melbourne, FL). The

aggregate data file was then analyzed along the axis in which the diode array was shifted. For example,
the typical data dimensions for a diode array text file are 65 × 53, which corresponds to the number of
diodes in each direction with 1-cm spacing along vertical and horizontal axes. With the 1-mm shift applied
in one direction along one of the axes in 2-D space, the number of columns expanded to 270 for the
coronal left/right shift and the number of rows expanded to 330 for the superior/inferior shift. This
represents the initial position of the diodes with an additional 9 data points to fill in the 1-cm gap between
diodes along a given axis.

2.2.5 Reproducibility
Measurement sessions occurred on separate days and therefore required repeated construction
of the experimental setup; therefore, assuring reproducibility in setup was crucial to the developed design.
Measurements taken through isocenter for the lung SBRT and SSRS plans were replicated for shifts
along the coronal left/right axis and the coronal superior/inferior axis. For the posteriorly positioned 2.0 cm
and 2.7 cm SSRS plan deliveries, shifts in the diode array were only applied along the coronal left/right
axis. Reproducibility was only assessed using the aggregate data files of the coronal left/right axis for the
posteriorly positioned SSRS plans. Experimental reproducibility was assessed by overlaying the
aggregate measured dose distributions for a given shift within the coronal plane and calculating the
positional alignment error and shift in isodose levels, which are described in the following section.

2.3 Aim 3
Delivery accuracy was quantified using three analysis metrics: percent difference between
measured and planned dose values, positioning alignment, and difference in isodose levels. After the
measurements were analyzed, additional tests were required to explain the results from the delivery of
the treatment plans.
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2.3.1 Analysis Metrics
Percent Difference
Due to a noticeable dose discrepancy in the center of the SSRS profile between the measured
dose delivery and that generated by the treatment planning system, the percent difference between the
measured and planned value for the center point in the MapCHECK2 array was calculated using the
standard formula:
% 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 =

(𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝 𝐝𝐨𝐬𝐞 𝐯𝐚𝐥𝐮𝐞 − 𝐩𝐥𝐚𝐧𝐧𝐞𝐝 𝐝𝐨𝐬𝐞 𝐯𝐚𝐥𝐮𝐞)
× 𝟏𝟎𝟎
𝐩𝐥𝐚𝐧𝐧𝐞𝐝 𝐝𝐨𝐬𝐞 𝐯𝐚𝐥𝐮𝐞

(1)

The percent difference of the measured and planned center point dose value was only calculated for the
SSRS coronal left/right plane with a 2 cm and 2.7 cm posterior shift. The center point in these planes
represents the approximate location of the spinal cord in the plan, specifically where it abuts to the
vertebral column (2cm profile) and the center of the spinal cord (2.7 cm profile). Percent difference was
calculated for this point, in particular, due to the strict dose tolerance of the spinal cord and the potential
for large overdoses due to inaccurate treatment delivery. Percent difference between measured and
calculated dose points was not calculated for the deliveries of the lung SBRT or spine SRS plans through
the coronal plane at isocenter.
Positional Alignment Error
The positional alignment error (Δc) for those measurements taken at isocenter with no posterior
shift applied was defined as the displacement between the center of the planned and measured profiles
(defined as the midpoint between the 75% dose levels on each side of the profile):
Δc = ½ (X75%,TPS+ + X75%,TPS-) – ½ (X75%,Meas+ + X75%,Meas-)

(2)

Where X75% refers to the position of the 75% maximum dose point as calculated by the TPS and
subscripts (+) and (-) refer to the slopes of the profile while moving across the profile from patient left to
patient right or patient inferior to patient superior respectively. The 75% dose value was selected as it is
located near the point of steepest dose gradient. Because 100% dose refers to an absolute maximum
dose of 2046 cGy as calculated by the TPS for the lung SBRT plan transferred to the diode array
phantom, the 75% dose correspond to an absolute dose of 1535 cGy. Similarly, the 100% dose refers to
an absolute maximum dose of 3784 cGy as calculated by the TPS for the spine SRS plan, which makes
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the 75% dose corresponds to 2838 cGy. The 75% dose point was used to calculate the positional
alignment error those profiles taken along the patient left-right axis and the patient superior-inferior axis
for the lung SBRT and spine SRS treatment delivery profiles of the coronal plane taken through isocenter.
The positional alignment error (Δc) for the SSRS measurements taken at additional posterior
alignments of 2cm and 2.7cm was defined as the displacement between the center of the planned and
measured profiles (defined as the midpoint between the 60% dose levels on each outer side of the
profile):
Δc = ½ (X60%,TPS+ + X60%,TPS-) – ½ (X60%,Meas+ + X60%,Meas-)

(3)

Where X60% refers to the position of the 60% maximum dose point as calculated by the TPS and
subscripts (+) and (-) refer to the slopes of the profile while moving across it from patient left to patient
right respectively. The 60% maximum dose point was used for the posteriorly offset SSRS profiles
because the 75% maximum dose point was not applicable for one or more profiles as they did not receive
this dose during delivery due to the high dose gradient across profiles. Rather, a lower percentage of the
maximum dose point was chosen because it similarly corresponds to the approximate point of the
sharpest dose gradient as the 60% maximum dose value corresponds to 2270 cGy of the SSRS absolute
maximum dose. Positional alignment error was only calculated for the patient left-right axis for the
posteriorly offset SSRS treatment delivery, as shifts in the diode array were not made along the patient
superior-inferior axis.
Overall, the value of Δc is a degree of the alignment error in a measurement, where positive
values indicate a shift of the measured profile in the left or inferior direction and negative values indicate a
shift in the right or superior direction relative to the planned profile (Sutton et al., 2014).
Difference in the 75% and 60% Dose Levels
Shifts in the 75% dose level (Δ75) represented the asymmetric deviations in the 75% isodose
lines within the profiles of the coronal plane of delivered lung SBRT and SSRS plans taken through
isocenter. Moreover, the shift in dose point served as an evaluation of coverage of the tumor volume. The
75% dose level shifts were defined as:
Δ75Right = 75%TPS,R – 75%Meas,R

(4)

Δ75Left = 75%Meas,L – 75%TPS,L

(5)
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Δ75Superior = 75%TPS,S – 75%Meas,S

(6)

Δ75Inferior = 75%Meas,I – 75%TPS,I

(7)

Where the subscripts R, L, S, and I denote the right, left, superior, and inferior sides of the profile,
respectively. Positive values of Δ75 indicated that the position of the measured 75% isodose fell inside
the calculated (planned) 75% isodose line. Conversely, negative values of Δ75 indicated that the
measured 75% isodose line fell outside the calculated (planned) 75% isodose line.
Differences in the 60% isodose levels (Δ60) represented the asymmetric deviation and the
coverage of the target volume in the 60% isodose lines within the profiles of the delivered SSRS plan
posteriorly offset by 2cm and 2.7cm. Shifts in the 60% dose level were defined as:
Δ60Right = 60%TPS,R – 60%Meas,R

(8)

Δ60Left = 60%Meas,L – 60%TPS,L

(9)

With the same defining characteristics as Δ75. Of note, Δ60Superior and Δ60Inferior were not calculated for
the posteriorly aligned diode array for the delivery of the SSRS treatment plan because shifts were made
only along the patient left-right axis.
A sample profile has been provided that demonstrates the metrics previously described, including
the positional alignment error and the difference in isodose levels (Figure 2.15). For the chosen profile,
Figure 2.15 displays Δ75 for one of the lung SBRT treatment plan deliveries.

Figure 2.15. Sample profile illustrating the positional alignment error and difference in75% isodose level
metrics on a profile of the delivered and calculated lung SBRT treatment.

23

2.3.2 Delivery of Treatment Plans on Additional Linear Accelerators
Additional measurements were collected across three linear accelerators to test for differences
between the delivery capabilities and performance of each unit. Using the same methods previously
described (Section 2.2.2), the lung SBRT treatment plan and the SSRS treatment plan offset posteriorly
by 2.0 cm and 2.7 cm were delivered on two additional linear accelerators: the Elekta Versa HD
accelerator and an additional Elekta Infinity

TM

TM

linear

with Agility head linear accelerator. Measurement sessions

utilized the XVI system to acquire kV-CBCT images to aid in positioning the MapCHECK2 diode array
(Section 2.2.3).

2.3.3 Individual Gantry Beam Measurements
To further assess the dose discrepancy in treatment delivery of the spine SRS plan, each
treatment field was delivered at the prescribed gantry angle as well as at 0° to the MapCHECK2 with
MapPHAN for the 2.0 cm and 2.7 cm posteriorly shifted measurement sessions. The planar dose for each
beam with the corresponding posterior offset of either 2.0 or 2.7 cm was generated with the same method
as described in section 2.1.3. Additionally, to isolate the planar dose for each beam at its planned gantry
and collimator angle, the number of monitor units was set to zero for all beams but one before exporting
the file. For the delivery of the beams at gantry and collimator angle 0, the orientation of the beams were
manually modified while leaving the MLC control points the same, which resulted in the delivery of the
same number of monitor units and MLC leaf configuration for each beam.
Individual beam measurements were taken with the diode array posteriorly offset by 2.0 and 2.7
cm and the fields delivered at their planned angle. An additional measurement consisted of the treatment
beams delivered at 0° for the gantry and collimator angles. By delivering the beams at gantry angle 0°
and collimator angle 0°, the potential for over-response from the diodes resulting from oblique gantry
angles was minimized. Analysis of the data was performed using the aforementioned percent difference
formula for the center point of the measured and calculated treatment plan.

2.3.4 Ion Chamber Measurements
Because diodes have been reported to exhibit directional dependence (Jursinic, 2009; Keeling et
al., 2013; Jursinic et al., 2010), additional measurements were required to determine the cause of a
specific discrepancy between the TPS calculated dose and the measured dose to the (0,0) point in the
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SSRS plan with an applied posterior offset of 2 cm and 2.7 cm. To establish whether the measured dose
at this point was actually being delivered or the potential result of over-responding diodes, the absolute
dose was measured with an Exradin A1SL ion chamber (Standard Imaging, Inc., Middleton,WI; SN:
XW120896) inserted in a cylindrical, solid water “cheese” phantom with radius of 15 cm and a width of 18
cm (Accuray, Inc. TomoTherapy©, Sunnyvale, CA). Measurement readings were recorded from the
CNMC Instruments Inc. Model 206 Dosimetry Electrometer. The SSRS treatment plan was copied to an
image set of the “cheese” phantom, and the dose to the approximate active detector volume of the A1SL
ion chamber located 2 cm and 2.7 cm posterior to the isocenter point was calculated for each treatment
3

beam using the TPS. The volume of the A1SL ion chamber is 0.053 cm and the volume contoured was
3

0.063 cm ; the exact volume of the chamber could not be contoured since the CT slice is 2.5 mm,
therefore limiting the range of volume that could be contoured. The ion chamber was then placed in the 2cm posterior insert within the phantom and three measurements for each beam were acquired and
averaged for dose calculations (Figure 2.25). Since no insert exists for a 2.7 cm shift, the table was
shifted down by 0.7 cm for this additional measurement. Using an adaptation of the TG-51 formalism
(Almond et al., 1999) to determine the photon dose, the absorbed dose to water was calculated and
converted to absorbed dose for muscle using the formula below:
𝑫𝒐𝒔𝒆 (𝒎𝒖𝒔𝒄𝒍𝒆) = 𝑷𝒊𝒐𝒏 ∗ 𝑷𝑻𝑷 ∗ 𝑷𝒆𝒍𝒆𝒄 ∗ 𝑷𝒑𝒐𝒍 ∗ 𝑴𝒓𝒂𝒘 ∗ 𝒌𝒒 ∗ 𝑵𝑪𝒐!𝟔𝟎
×
𝑫,𝒘

𝝁
𝝆

𝒎𝒖𝒔𝒄𝒍𝒆

(10)

𝒘𝒂𝒕𝒆𝒓

Where 𝑀!"# represents the uncorrected ion chamber reading, 𝑃!"# is the recombination correction factor
that takes into account the incomplete collection of charge from an ion chamber, 𝑃!" is the temperaturepressure correction factor which makes the charge correspond to the standard environmental conditions
for which the calibration factor applies, 𝑃!"!# represents the electrometer correction factor, and 𝑃!"# is the
polarity correction factor which takes into account any polarity effect in the response of the ion chamber.
Additionally, 𝑘! is the quality conversion factor that accounts for the change in the absorbed-dose to
water calibration factor between the beam quality of interest, Q, and the beam quality of Co-60 for which
!"!!"
the absorbed-dose calibration factor applies. 𝑁!,!
represents the absorbed-dose to water calibration

factor for an ion chamber located under reference conditions in a radiation beam of Co-60 beam quality.
Since dose to muscle is the quantity of interest in clinical dosimetry, absorbed dose to water must be
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converted to absorbed dose to muscle in order to compare those values generated by the TPS to what
!

was measured. The mass energy absorption coefficient ratio between muscle and water, ( )!"#$%&
!"#$% , was
!

used to convert the absorbed dose in water to the absorbed dose in muscle.

Figure 2.16. Solid water “cheese” phantom with ion chamber placed in 2cm patient posterior insert.
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Chapter 3. Results
3.1 Results of Treatment Planning
3.1.1 Lung SBRT Treatment Plan
The lung SBRT treatment plan was designed to follow dose constraints outlined by RTOG Report
0813, which can be found in Table 3.1. Specifically, the maximum dose of the treatment plan requires that
100% corresponds to the maximum dose delivered to the patient that must occur within the PTV. The
prescription isodose surface had to be ≥60% and ≤90% of the maximum dose. The prescription isodose
surface coverage constraint requires at least 95% of the PTV receive the prescription dose (V100 ≥ 95%)
and that 99% of the PTV receive a minimum of 90% of the prescription dose dose (V90 ≥ 99%). Lastly, the
constraint for high dose spillage limited the volume of tissue outside the PTV to be no greater than 15% of
the PTV volume that received a dose >105% of the prescription dose.
Table 3.1: RTOG 0813 Protocol Requirements
Criteria
Constraint
Maximum Dose
100% corresponds to the maximum dose
delivered to the patient; point must exist within
the PTV
Prescription Isodose
≥60% and ≤90%
Prescription Isodose Surface Coverage
PTV V100 = 95% and PTV V90 > 99%
High Dose Spillage
Cumulative volume of all tissue outside the PTV
receiving >105% of prescription dose ≤ 15% of
the PTV volume
Additionally, the generated lung SBRT treatment plan also met the requirements for conformality
3

of prescribed dose described subsequently. With a PTV of 57.45 cm , the RTOG 0813 requirements were
met (Figure 3.1). Specifically, the ratio of prescription isodose volume to the PTV volume did not exceed
the ratio requirement of 1.5 for the PTV volume. Also, the ratio of 50% prescription isodose volume to the
PTV volume (R50%) and maximum dose in percent of dose prescribed at 2 cm from PTV in any direction
[D2cm (%)] did not exceed the requirements as listed in RTOG Report 0813. With all constraints and
requirements met, the lung SBRT treatment plan met all stated RTOG requirements.
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Figure 3.1. Scorecard containing objectives for the lung SBRT plan.

3.1.2 SSRS Treatment Plan
The SSRS treatment plan met the protocol requirements of RTOG Report 0631 as shown in
Table 3.2. Figure 3.2 displays the scorecard from the treatment planning system. Of note, the maximum
dose to the spinal cord was 1011.2 cGy, which was well below the maximum dose constraint of 1400
cGy. Moreover, the treatment plan design achieved a prescribed dose of 16 Gy in one fraction to cover at
least 90% of the CTV as well as 90% coverage to the GTV that received 24 Gy. Since all goals and
constraints were met, the SSRS treatment plan was considered clinically acceptable and used for end-toend testing to assess the delivery accuracy of multiple Elekta linear accelerators.
Table 3.2. RTOG 0631 Protocol Requirements and MBPCC Constraints
Organ at Risk (OAR)
Constraint
Spinal Cord
Max Dose ≤ 14 Gy
Spinal Cord
12 Gy to less than 0.01cc
Kidney
Max Dose of 10 Gy
Liver
Max Dose of 10 Gy
Stomach
Max Dose of 11 Gy
Bowel
Max Dose of 15 Gy
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Figure 3.2. Scorecard containing objectives for the spine SRS plan.

3.2 MV Isocenter Accuracy Test Results
Table 3.3 contains the results of the MV Isocenter Accuracy test for the three linear accelerators
used for this study. Infinity 1 refers to the Elekta Infinity™ with Agility head located at the MBPCC Baton
Rouge site. Versa HD refers to the Elekta Versa HD™ linear accelerator, also located at the MBPCC
Baton Rouge site. Moreover, Infinity 2 refers to the additional Elekta Infinity™ with Agility head linear
accelerator located at the MBPCC Gonzales site. Per the 6 MV Isocenter Customer Acceptance protocol,
MV isocenter radius for gantry rotation has a limit of ≤ 0.70 mm. Additionally, the limit of the MV isocenter
radius for the combined gantry and treatment table rotation is ≤1.00 mm. For the Infinity 1 and Versa HD
linear accelerators, the maximum MV isocenter radius for both the gantry and treatment table rotation
was a result of the gantry rotation, which is why the radius for gantry rotation and combined gantry and
treatment table rotation are the same. Since the results of the MV isocenter accuracy test was within
tolerance for the MV isocenter radius for the combined gantry and treatment table rotation and only a
maximum of 0.01 mm from being within tolerance for the gantry rotation for all three linear accelerators,
no adjustments were made to the mechanical aspects of the delivery system to improve the radius of
isocenter.
Table 3.3. Results of the MV Isocenter Accuracy Test for three linear accelerators.
MV Isocenter Radius for
MV Isocenter Radius for
Linear Accelerator
Combine Gantry and
Gantry Rotation (mm)
Treatment Table Rotation (mm)
Infinity 1
0.71
0.71
Versa HD
0.69
0.69
Infinity 2
0.65
0.87
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3.3 Results of Treatment Deliveries
3.3.1 Reproducibility of Diode Array Setup
The reproducibility of the experimental setup was evaluated by overlaying repeated delivered
treatment plans that were shifted in the same direction. Table 3.4 contains the average positional
alignment error between two measured trials of the treatment delivery of the lung SBRT and spine SRS
plan. Equations 2 and 3 were used to calculate the positional alignment (Δc) between the two measured
profiles, where the midpoint value for the TPS-calculated value was replaced with the midpoint value from
trial 1 and the midpoint value of trial 2 was subtracted. Positive Δc values indicated a left or inferior shift of
trial 2 relative to trial 1. Tables 3.5 and 3.6 display values for the shift in 75% isodose levels between
measured deliveries. Equations 4-7 were used to calculate the difference in isodose levels. Δ75Right and
Δ75Superior were calculated by subtracting the 75% dose level position of trial 2 from the 75% isodose level
position of trial 1. Δ75Left and Δ75Inferior were calculated by subtracting the 75% isodose level position of
trial 1 from that of trial 2. Similarly, the values for Δ60 in Table 3.7 were calculated in the same manner for
those profiles that were posteriorly offset. Positive Δ75 and Δ60 values indicate that the profile of trial 2
fell within the profile of trial 1. Conversely, negative Δ75 and Δ60 values indicate that the profile for trial 2
fell outside that of trial 1. Ideally, positional alignment and shifts in the isodose levels would be zero if
there were no uncertainties within the setup. However, the values from Tables 3.4 - 3.7 indicate that the
uncertainty in the reproducibility of the setup was less than 1mm on average. Figures 3.3 - 3.8 display
sample overlaid profiles taken through the central axis of the measured deliveries. Overall, the precision
of repeated measurements of the same plan with device setup re-constructed for each session was
quantified and deemed acceptable based on the slight deviances from one measurement session to the
next.
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Table 3.4. Average positional alignment comparison between two measured treatment delivery trials
demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity linear accelerator with
Agility head. Positive values of Δc indicate a left or inferior shift of trial 2 relative to trial 1. Conversely,
negative values of Δc indicate a right or superior shift of trial 2 relative to trial 1.
Direction of
Average Δc
Minimum Δc
Maximum
Treatment Plan
Profile
(mm)
(mm)
Δc (mm)
Lung SBRT
Left-Right
0.13
0.08
0.17
Lung SBRT
Superior-Inferior
-0.13
-0.24
-0.04
SSRS
Left-Right
0.08
-0.03
0.15
SSRS
Superior-Inferior
-0.21
-0.62
-0.07
SSRS, 2 cm
Left-Right
-0.61
-0.69
-0.55
SSRS, 2.7 cm
Left-Right
-0.16
-2.46
0.56
Table 3.5. Average shift in 75% isodose level comparison between two measured treatment delivery trials
demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity linear accelerator with
Agility head. Values are for profiles of 1-mm resolution along the patient left-right axis, where a positive
Δ75Left or Δ75Right indicates the trial 2 isodose level fell within the trial 1 profile. Conversely, a negative
Δ75Left or Δ75Right indicates the trial 2 isodose level fell outside the trial 1 profile.
Average
Minimum
Maximum
Average
Minimum Maximum
Treatment
Δ75Left
Δ75Left
Δ75Left
Δ75Right
Δ75Right
Δ75Right
Plan
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
Lung
-0.14
-0.30
-0.01
0.12
-0.03
0.32
SBRT
SSRS
-0.04
-0.16
0.13
0.12
0.05
0.20
Table 3.6. Average shift in 75% isodose level comparison between two measured treatment delivery trials
demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity linear accelerator with
Agility head. Values are for profiles of 1-mm resolution along the patient superior-inferior axis, where a
positive Δ75Inferior or Δ75Superior indicates the trial 2 isodose level fell within the trial 1 profile. Conversely, a
negative Δ75Inferior or Δ75Superior indicates the trial 2 isodose level fell outside the trial 1 profile.
Average
Minimum
Maximum
Average
Minimum Maximum
Treatment
Δ75Inferior
Δ75Inferior
Δ75Inferior
Δ75Superior Δ75Superior Δ75Superior
Plan
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
Lung
0.05
-0.06
0.12
-0.24
-0.37
-0.13
SBRT
SSRS
0.29
0.05
0.71
-0.13
-0.53
0.07
Table 3.7. Average shift in 60% isodose level comparison between two measured treatment delivery trials
with posterior offsets demonstrating reproducibility of setup for treatment deliveries on the Elekta Infinity
linear accelerator with Agility head. Values are for profiles of 1-mm resolution along the patient left-right
axis, where a positive Δ60Left or Δ60Right indicates the trial 2 isodose level fell within the trial 1 profile.
Conversely, a negative Δ60Left or Δ60Right indicates the trial 2 isodose level fell outside the trial 1 profile.
Average
Minimum
Maximum
Average
Minimum Maximum
Treatment
Δ60Left
Δ60Left
Δ60Left
Δ60Right
Δ60Right
Δ60Right
Plan
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
SSRS,
0.40
0.26
0.49
-0.82
-0.89
-0.73
2cm
SSRS,
-0.41
-0.77
-0.13
0.55
0.21
1.32
2.7cm
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Figure 3.3. Profiles of repeated measurements for the lung SBRT plan in the coronal plane taken at 0 cm
along the superior-inferior axis; used for determining reproducibility of the experimental setup.
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Figure 3.4. Profiles of repeated measurements for the lung SBRT plan in the coronal plane taken at 0 cm
along the left-right axis; used for determining reproducibility of the experimental setup.
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Figure 3.5. Profiles of repeated measurements for the spine SRS plan in the coronal plane taken at 0 cm
along the superior-inferior axis; used for determining reproducibility of the experimental setup.
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Figure 3.6. Profiles of repeated measurements for the spine SRS plan in the coronal plane taken at 0 cm
along the left-right axis; used for determining reproducibility of the experimental setup.
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Figure 3.7. Profiles of repeated measurements for the spine SRS plan posteriorly offset by 2 cm in the
coronal plane taken at 0 cm along the superior-inferior axis; used for determining reproducibility of the
experimental setup.
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Figure 3.8. Profiles of repeated measurements for the spine SRS plan posteriorly offset by 2.7 cm in the
coronal plane taken at 0 cm along the superior-inferior axis; used for determining reproducibility of the
experimental setup.
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An example profile taken from Appendix A has been included to illustrate a feature that resulted
from the aggregate file of the combined 1-mm shifts of the diode array. Shown in Figure 3.9 is a profile
from the delivery of the lung SBRT treatment plan on the Elekta Infinity linear accelerator taken through
the superior-inferior point of 0.5cm (Y = 0.5cm). Figure 3.9 (A) is an analysis performed by the SNC
Patient Software of one of the nine individual files that were combined to form the aggregate data file with
1-mm resolution along a single axis, Figure 3.9 (B). The diode within the green circle (A) measured a
higher dose than the diodes directly adjacent to it. When the individual files were combined to form the
aggregate this resulted in an artifact resembling a plateau that is highlighted with the green circle in
Figure 3.9 (B). These characteristics are found in several of the measured profiles that were used for
analysis in this research. The data points in Figure 3.9 (A) represent distinct measured diode doses that
when they were combined created a smearing effect seen in Figure 3.9 (B).

Figure 3.9. (A) SNC Patient Software profile of a single delivery of the lung SBRT plan analyzed at the
native resolution of the diode array. (B) Sample plotted profile of the aggregate data file for 9 sequential
deliveries of the lung SBRT plan, including that of (A).
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3.3.2 Analysis of Treatment Delivery
Figures 3.10, 3.11, and 3.12 are comparisons between the calculated and delivered treatment
plans created in Aim 1 and delivered with the methods described for Aim 2. Specifically, Figure 3.10
shows lung SBRT profiles taken through Y = 0 cm for three linear accelerators as well as the calculated
profile from the TPS. Measurement sessions for the delivery of the lung SBRT plan did not utilize kVCBCT imaging for setup. Overall, agreement between the planned and delivered lung plan profiles was
similar across all linear accelerators. Quantitative comparisons follow in the subsequent sections.
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Figure 3.10. Comparison of profiles the planned and delivered lung SBRT treatment plan on three linear
accelerators; profiles were taken through Y = 0cm on superior-inferior axis.
Conversely, the agreement across linear accelerators for the delivery of the SSRS plan varied, as
seen in Figures 3.11 and 3.12. Both measurement sessions for the posteriorly offset diode array for the
SSRS delivery utilized kV-CBCT imaging for experimental setup. Figure 3.11 displays the overlaid profiles
taken through Y = 0 cm for the three linear accelerators as well as the calculated TPS profile for the
SSRS treatment plan through the 2-cm posterior coronal plane. Upon visual inspection, large
discrepancies can be seen at the center of the profile, which represents the area where the spinal cord is
adjacent to the vertebral column. As previously stated, this profile falls within a high dose gradient region
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so variability was expected due to the fact that a sub-millimeter misalignment in the anterior-posterior
direction could result in a drastically different dose. However, the degree of variability (see Table 3.8) that
resulted from the treatment deliveries led to further analysis described in the following sections. Similar
results can be seen in Figure 3.12 that displays the overlaid profiles taken through Y = 0 cm for the
calculated and delivered SSRS treatment plan through the 2.7-cm posterior coronal plane. A similar dose
discrepancy between planned and calculated values at the center of the profile for the 2.7 cm posterior
offset coronal plane (representing the region of the spinal cord) can be seen in Figure 3.12.

Spine SRS Coronal Left-Right
2cm Posterior Offset Profiles of 3 Elekta Linear Accelerators
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Figure 3.11. Comparison of the center profiles of the planned and delivered spine SRS treatment plan
posteriorly shifted by 2 cm on three linear accelerators profiles; were taken through Y = 0 cm on superiorinferior axis.
Percent Difference
Table 3.8 shows the percent difference calculated for the central diode of the delivered SSRS
treatment plans shifted posteriorly by 2 cm and 2.7 cm as compared to the planned dose for the central
diode on the TPS-generated planar dose. As previously stated, the central diode was chosen in the
coronal left-right profile to represent the approximate position of the junction of the spinal cord and
vertebral column, at the 2 cm profile, and the center of the spinal cord, at the 2.7 cm profile. The
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measured dose at the center point of the profile was consistently higher than that which was planned,
suggesting a systematic difference between measurement and calculation.

Spine SRS Coronal Left-Right
2.7cm Posterior Offset Profiles of 3 Elekta Linear Accelerators
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Figure 3.12. Comparison of the center profiles of the planned and delivered spine SRS treatment plan
posteriorly shifted by 2.7 cm on three linear accelerators; profiles were taken through Y = 0 cm on
superior-inferior axis.
Table 3.8. Percent Difference between TPS calculated dose and delivery of the treatment plan measured
dose at the central point of the MapCHECK2 diode array. All measurements were taken in the coronal
plane along the right-left direction.
Measured
TPS Value
Posterior
Linear
Value at
at Center
Percent
Trial
Offset
Accelerator
Center Point
Point
Difference
(cm)
(cGy)
(cGy)
Infinity 1
1
2.0
1198.2
960.5
24.75%
Infinity 1
2
2.0
1168.7
960.5
21.67%
Versa HD
1
2.0
1339.0
960.5
39.41%
Infinity 2
1
2.0
1112.2
960.5
15.79%
Infinity 1
1
2.7
592.6
485.3
29.32%
Infinity 1
2
2.7
585.6
485.3
27.78%
Versa HD
1
2.7
622.4
485.3
35.83%
Infinity 2
1
2.7
535.3
485.3
16.81%
Positional Alignment Error
Table 3.9 contains the data corresponding to the average positional alignment error (Δc) between
the measured and planned lung SBRT and SSRS profiles taken through Y = 0, -0.5, -1, 0.5, and 1 cm for
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the left-right direction and X = 0, -0.5, -1, 0.5, and 1 cm for the superior-inferior direction (see Appendix
A). The range, displayed as minimum and maximum values, was also calculated. The meanings of
positive and negative values of Δc were described in Section 2.3.1. 2-mm accuracy has been achieved
for lung SBRT treatment delivery with a 1-mm accuracy achieved for spine SRS treatments (see Section
1.2), therefore these values served as the standard for the positional alignment error of the delivered
treatment plans. Ideally, all data points would align on the central axis specific to the direction of the
increased resolution. For example, those measurements with 1-mm resolution in the left-right direction
would ideally have a positional alignment error of zero along the y-axis and vice versa for those
measurements with 1-mm resolution in the superior-inferior direction. Overall, average positional
alignment indicated a shift of the measured profile in the left or inferior direction due to the primarily
positive values.
Table 3.9. Summary of Δc analysis metric for the delivery of the lung SBRT and SSRS treatment plans
delivered on three linear accelerators. Positive values of Δc indicate a shift of the measured profile in the
left or inferior direction relative to the planned profile. Negative values of Δc indicate a shift in the right or
superior direction relative to the planned profile.
Linear
Treatment
Direction of
Average
Minimum
Maximum
Accelerator
Plan
Profile
Δc (mm)
Δc (mm)
Δc (mm)
Infinity 1
Lung SBRT
Left-Right
0.3
-0.1
1.2
Infinity 1
Lung SBRT
Superior-Inferior
0.2
-0.7
0.6
Versa HD
Lung SBRT
Left-Right
0.5
0.0
1.6
Infinity 2
Lung SBRT
Left-Right
0.4
0.0
1.0
Infinity 1
SSRS
Left-Right
-0.1
-0.5
0.4
Infinity 1
SSRS
Superior-Inferior
0.4
-0.5
1.3
Infinity 1
SSRS, 2 cm
Left-Right
0.5
-0.2
1.3
Versa HD
SSRS, 2 cm
Left-Right
0.2
-0.3
0.8
Infinity 2
SSRS, 2 cm
Left-Right
0.0
-0.4
0.4
Infinity 1
SSRS, 2.7 cm
Left-Right
0.6
-0.8
1.7
Versa HD
SSRS, 2.7 cm
Left-Right
0.4
-0.4
1.1
Infinity 2
SSRS, 2.7 cm
Left-Right
-0.6
-1.9
0.2
Shift in 75% and 60% Isodose Level
Table 3.10 and 3.11 show the average values of the shifts in the 75% dose points (Δ75) for the
profiles of the delivered lung SBRT and SSRS plans with isocentric setup. Profiles were taken through Y
= 0, -0.5, -1, 0.5, and 1 cm for the evaluation of Δ75Left and Δ75Right with profiles taken through X = 0, -0.5,
-1, 0.5, and 1 cm for the evaluation of Δ75Superior and Δ75Inferior (see Appendix A). Specifically, Table 3.10
displays the values for Δ75Left and Δ75Right as well as the minimum and maximum of calculated values
corresponding to the measurements with a resolution of 1 mm in the left-right direction, while Table 3.11
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contains values for Δ75Superior and Δ75Inferior as well as the minimum and maximum values, which
correspond to the measurements with a resolution of 1 mm in the superior-inferior direction. The values of
Δ75 represent the asymmetric deviations in the 75% isodose lines between the measured and planned
profiles (Section 2.3.1).
Table 3.10. Δ75Left and Δ75Right for lung SBRT and spine SRS profiles on three linear accelerators.
Positive values of Δ75Left and Δ75Right indicated that the position of the measured 75% isodose line fell
inside the planned 75% isodose line. Negative values of 75Left and Δ75Right indicated that the measured
75% isodose line fell outside the planned 75% isodose line.
Average Minimum Maximum Average Minimum Maximum
Linear
Treatment
Δ75Left
Δ75Left
Δ75Left
Δ75Right
Δ75Right
Δ75Right
Accelerator
Plan
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
Lung
Infinity 1
-1.2
-2.1
-0.4
-0.5
-1.4
0.4
SBRT
Lung
Versa HD
-0.8
-1.9
0.4
0.2
-0.7
1.3
SBRT
Lung
Infinity 2
-0.2
-0.6
0.1
0.6
0.2
1.5
SBRT
Spine
Infinity 1
-0.7
-1.7
0.2
-0.8
-1.3
-0.3
SRS
Table 3.11. Δ75Superior and Δ75Inferior for lung SBRT and spine SRS profiles on an Elekta Infinity linear
accelerator. Positive values of Δ75Superior and Δ75Inferior indicated that the position of the measured 75%
isodose line fell inside the planned 75% isodose line. Negative values of 75Superior and Δ75Inferior indicated
that the measured 75% isodose line fell outside the planned 75% isodose line.
Average Minimum Maximum Average Minimum Maximum
Linear
Treatment
Δ75Superior Δ75Superior Δ75Superor Δ75Inferior Δ75Inferior
Δ75Inferior
Accelerator
Plan
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
Lung
Infinity 1
-0.6
-1.9
0.2
-0.9
-1.1
-0.5
SBRT
Spine
Infinity 1
0.0
-1.3
1.3
-0.9
-2.4
0.7
SRS
Table 3.12 contains the values of Δ60Left and Δ60Right that correspond to the delivery of the spine
SRS treatment plan shifted posteriorly by 2.0 or 2.7 cm on three different linear accelerators. For either
data session, 1 mm resolution was achieved in only the left-right direction.
Table 3.12. Δ60Left and Δ60Right for posteriorly offset spine SRS profiles on three linear accelerators.
Positive values of Δ60Left and Δ60Right indicated that the position of the measured 60% isodose line fell
inside the planned 60% isodose line. Negative values of 60Left and Δ60Right indicated that the measured
60% isodose line fell outside the planned 60% isodose line.
Average Minimum Maximum Average Minimum Maximum
Linear
Treatment
Δ60Left
Δ60Left
Δ60Left
Δ60Right
Δ60Right
Δ60Right
Accelerator
Plan
(mm)
(mm)
(mm)
(mm)
(mm)
(mm)
Spine SRS,
Infinity 1
-0.9
-1.6
-0.1
0.1
-0.5
1.0
2 cm
Spine SRS,
Versa HD
-0.7
-1.2
0.2
-0.2
-0.5
0.5
2 cm
(table continued)
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Linear
Accelerator
Infinity 2
Infinity 1
Versa HD
Infinity 2

Treatment
Plan
Spine SRS,
2cm
Spine SRS,
2.7 cm
Spine SRS,
2.7 cm
Spine SRS,
2.7 cm

Average
Δ60Left
(mm)

Minimum
Δ60Left
(mm)

Maximum
Δ60Left
(mm)

Average
Δ60Right
(mm)

Minimum
Δ60Right
(mm)

Maximum
Δ60Right
(mm)

-0.5

-0.9

0.0

-0.5

-0.8

0.0

-0.7

-2.3

0.4

-0.1

-2.8

1.7

-1.1

-2.0

1.1

-0.3

-2.7

0.9

1.2

-0.7

3.3

0.0

-0.9

1.9

3.4 Individual Gantry Beam Measurement Results
Tables 3.13 and 3.14 contain data for the delivery of individual gantry beams to the MapCHECK2
diode array at its native resolution with MapPHAN shifted posteriorly in comparison with the TPSgenerated planar dose. These measurements were taken to provide more insight concerning the diode
array’s performance and whether or not angular dependence and over-response were potential causes
for dose discrepancies in the region of the spinal cord. Specifically, Table 3.13 corresponds to data taken
at the approximate region where the spinal cord ROI is adjacent to the vertebral body, whereas Table
3.14 corresponds to measurements taken at the approximate region representing the center of the spinal
cord. Both measurement sessions displayed in Tables 3.13 and 3.14 resulted in overall high percent
differences indicating that there was a systematically higher dose delivered to the region of the spinal
cord for every prescribed gantry beam. Additional measurements were taken with the gantry and
collimator placed at 0° to determine if angular dependence was the cause of the consistently higher dose
delivered than planned.
Table 3.13. SSRS beams at planned gantry angles delivered to a diode array shifted posteriorly by 2 cm
on Versa HD linear accelerator.
Planned
Gantry
Measured Dose
Percent
Dose (cGy)
Angle
(cGy) at (0,0)
Difference
at (0,0)
100
85.19
38.93
118.83%
120
159.73
88.12
81.26%
140
207.98
171.87
21.01%
160
165.97
125.75
31.98%
180
59.83
51.97
15.12%
200
179.92
152.65
17.86%
220
241.16
175.19
37.66%
240
128.39
51.67
148.48%
260
91.69
31.79
188.42%
Total
1319.86
887.94
48.64%
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Table 3.14. SSRS beams at planned gantry angles delivered to a diode array shifted posteriorly by 2.7
cm on Versa HD linear accelerator.
Planned
Gantry
Measured Dose
Percent
Dose (cGy)
Angle
(cGy) at (0,0)
Difference
at (0,0)
100
13.69
10.81
26.64%
120
42.11
23.76
77.23%
140
67.30
38.70
73.90%
160
149.19
120.37
23.94%
180
61.31
52.86
15.99%
200
145.86
133.06
9.62%
220
85.33
45.43
87.83%
240
32.15
19.84
62.05%
260
16.94
14.27
18.71%
Total
613.88
459.10
33.71%
Table 3.15 displays the comparison between the TPS-generated planar dose and the data
collected for the individual beams of the SSRS treatment plan delivered at gantry and collimator angles of
0°. Delivering the treatment beams at these angles ostensibly eliminated any angular dependence of the
diode array since the beams were delivered perpendicularly to the diode array. However, these
measurements resulted in varying percent differences ranging from approximately -35% to 37% when the
beams were delivered perpendicularly incident to the diode array, as is its intended use. The results from
Table 3.15 suggest that angular dependence was not the cause of the systematic error seen in Tables
3.13 and 3.14 where the beams were delivered at the prescribed angles.
Table 3.15. SSRS beams delivered at gantry angle 0 and collimator angle 0 to a diode array on Versa HD
linear accelerator.
Planned
Gantry
Measured Dose
Percent
Dose (cGy)
Angle
(cGy) at (0,0)
Difference
at (0,0)
100
124.12
90.09
37.77%
120
312.27
252.31
23.76%
140
752.61
773.76
-2.73%
160
207.68
322.82
-35.67%
180
49.00
47.79
2.53%
200
327.35
428.34
-23.58%
220
683.63
696.94
-1.91%
240
325.30
324.9
0.12%
260
326.42
343.92
-5.09%
Total
3108.38
3208.87
-5.26%
Further analysis of the SSRS treatment beams delivered at 0° for the gantry and collimator angle
led to the discovery that a 1-mm applied shift of the planar dose along the patient superior-inferior axis
resulted in smaller percent differences, as seen in Table 3.16. This shift most likely accounted for gantry
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sag that is prominent when the gantry is at 0° and 180°. With this shift applied, the delivery performance
of the SSRS beams were closer to what was expected based on the treatment planning system.
However, there was still variability as high as -12% between what was planned and what was measured
on the diode array. In order to confirm if this finding was a result of the chosen diode array dosimeter or a
result of an inaccuracy in the treatment planning system, a different experimental setup utilizing an ion
chamber dosimeter was used to measure the delivered dose for the same set of gantry angle
configurations as previously described.
Table 3.16. SSRS beams delivered at gantry angle 0 and collimator angle 0 to a diode array on Versa HD
linear accelerator. TPS Data was shifted by 1 mm along the Y-axis using SNC Patient™ Software,
resulting in smaller percent differences.
Planned
Gantry
Measured Dose
Percent
Dose (cGy)
Angle
(cGy) at (0,0)
Difference
at (0,0)
100
124.12
116.75
6.31%
120
312.27
291.41
7.16%
140
752.61
770.17
-2.28%
160
207.68
237.45
-12.54%
180
49.00
44.77
9.44%
200
327.35
351.66
-6.91%
220
683.63
687.78
-0.60%
240
325.30
329.42
-1.25%
260
326.42
333.58
-2.15%
Total
3108.38
3162.99
-1.73%

3.5 Ion Chamber Measurements
Tables 3.17 and 3.18 contain the data acquired using an ion chamber in the solid water “cheese”
phantom at the specific points that represent the perimeter of the spinal cord ROI (Table 3.17) and center
of the spinal cord (Table 3.18) as they compare to the TPS-generated values at the corresponding points
of interest. These measurements were acquired with the beams at their planned gantry and collimator
angles. The percent difference between the measured and planned values at both posterior positions was
not negligible with regards to the anatomical point of interest they represent. Moreover, the consistently
higher dose delivered agrees with the results from the central diode measurements seen in Tables 3.13
and 3.14. The data from the ion chamber measurements shown in Tables 3.17 and 3.18 confirmed that
the delivered dose measured by the diode array was valid, therefore suggesting an error in the treatment
planning system’s beam modeling algorithm.

43

Table 3.17. Ion chamber measurements for an active detector volume representing the approximate
region where the spinal cord ROI is adjacent to the vertebral body (2 cm from the CTV isocenter). Beams
were delivered at their planned gantry and collimator angles.
TPS
TPS
TPS Standard
Gantry Measured
TPS Mean
Percent
Minimum
Maximum
Deviation
Angle
(cGy)
Dose (cGy)
Difference
(cGy)
(cGy)
(cGy)
100
93.33
30.1
132.9
72.2
27.5
29.27%
120
150.43
41.4
253.1
120.9
51.3
24.43%
140
151.98
77.8
221.3
134.0
30.7
13.42%
160
118.33
56.8
128.6
89.2
23.6
32.66%
180
47.48
38.3
49.7
43.3
3.4
9.65%
200
133.37
94.4
171.8
123.9
18.2
7.64%
220
163.78
56.7
280.5
147.6
54.5
10.96%
240
100.32
31.1
191.8
75.9
39.0
32.17%
260
107.04
27.8
156.9
60.0
27.0
78.40%
Total
1066.06
867.0
22.96%
Table 3.18. Ion chamber measurements for an active detector volume representing the approximate
center of the spinal cord (2.7 cm from the CTV isocenter). Beams were delivered at their planned gantry
and collimator angles.
TPS
TPS
TPS Standard
Gantry Measured
TPS Mean
Percent
Minimum
Maximum
Deviation
Angle
(cGy)
Dose (cGy)
Difference
(cGy)
(cGy)
(cGy)
100
16.02
11.4
18.2
14.0
1.5
14.46%
120
28.26
15.9
37.3
21.8
4.0
29.62%
140
44.89
22.7
69.0
39.3
8.4
14.21%
160
97.73
59.6
118.6
85.9
15.5
13.77%
180
49.62
39.9
51.8
45.1
3.6
10.02%
200
115.05
86.7
125.8
105.2
8.9
9.36%
220
59.48
29.9
84.0
43.3
10.2
37.37%
240
22.60
14.8
22.9
17.8
1.7
4.80%
260
20.09
14.2
23.4
17.6
1.9
14.16%
Total
453.73
390.0
16.34%
To further test the accuracy of the SSRS treatment plan beams’ delivery, the beams were
overridden to be delivered at gantry and collimator angles of 0° with the ion chamber placed 2.7 cm
posterior to isocenter to represent the center of the spinal cord. Table 3.19 displays the result of this
experiment where an improvement between the percent difference of the measured and calculated dose
to this region of interest can be seen. The results in Table 3.19 suggest that the prescribed gantry and
collimator angles for the SSRS treatment plan, in combination with the optimized modulation, are the
cause for the error in the TPS beam model.
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Table 3.19. Ion chamber measurements for an active detector volume representing the approximate
center of the spinal cord (2.7 cm from the CTV isocenter). Beams were overridden to be delivered at
gantry and collimator angles of 0°.
TPS
TPS
TPS Standard
Gantry Measured
TPS Mean
Percent
Minimum
Maximum
Deviation
Angle
(cGy)
Dose (cGy)
Difference
(cGy)
(cGy)
(cGy)
100
64.60
26.4
89.6
59.0
22.2
9.49%
120
176.80
109.4
216.0
161.6
37.0
9.41%
140
437.40
408.1
443.5
428.1
10.2
2.17%
160
158.40
70.7
267.1
164.8
60.6
-3.88%
180
35.50
29.6
37.7
33.3
2.5
6.61%
200
225.30
150.2
309.5
229.7
59.3
-1.92%
220
409.90
368.2
416.9
396.7
12.2
3.33%
240
195.90
177.8
203.0
188.7
7.3
3.82%
260
200.98
183.4
212.4
196.7
9.8
2.18%
Total
1904.78
1858.6
2.48%
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Chapter 4. Discussion
4.1 Summary of Results
This project provided quantitative data regarding the accuracy and precision of high-dose
treatments delivered with the Elekta Infinity and Versa HD linear accelerators. Baseline geometric
accuracy was established across all three linear accelerators through the MV isocenter accuracy test,
which produced results for the radius of isocenter within the limits of the vendor-provided protocol for two
of the three tested linear accelerators with the third linear accelerator’s isocenter radius varying by only
0.01 mm from the limit. Accuracy of dose delivery for two stereotactic treatment plans was assessed
through a novel quality assurance platform that allowed for the diode array to achieve 1-mm resolution
along one axis. The reproducibility of the experimental design was measured and found to have
acceptable positional alignment errors and shift in isodose levels of less than 1 mm.
Variability in delivery accuracy of the treatment plans occurred across all three linear
accelerators. Profile comparisons of the calculated and measured data from these measurements were
analyzed for characteristic positional alignment (Δc). For the delivery of lung SBRT treatment plans, 2mm accuracy for patient setup with the use of immobilization devices has previously been achieved
(Benedict et al., 2010; Wulf et al., 2000; Nagata et al., 2002). Our study proved the Elekta Infinity and
Versa HD linear accelerators were able to achieve 2-mm positional accuracy. The delivery of the spine
SRS treatment plan across all linear accelerators achieved less than a 1-mm accuracy on average that
has previously been reported for spine SBRT treatments (Guckenberger et al., 2007; Wang et al., 2008;
Chang et al., 2004). Yenice et al reported that errors of 2 mm in magnitude can result in a significantly
greater (>100%) dose to the spinal cord than planned (Yenice et al., 2003). The calculated percent
difference between measured and calculated dose values at the region representative of the spinal cord
reflected these findings. Even with kV-CBCT positioning, the difference between calculated and
measured doses showed a delivered dose to the region of the spinal cord as much as 39% higher than
intended. Therefore, achieving 1-mm positional accuracy is necessary when treating spine SRS cases so
as to avoid delivering a greater dose to OARs than planned.
Where the positional alignment varied among each linear accelerator, analysis of the differences
in specific isodose levels (Δ75 and Δ60) showed that, overall, the measured profile point fell outside the
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planned isodose line, meaning that the target volume was consistently covered with the prescribed dose
compared to the TPS calculation. The values of Δ75 and Δ60 varied by approximately 1.2 mm at most
for the lung SBRT and spine SRS, suggesting variable coverage of the target volume for the delivered
plan compared to that generated by the treatment planning system.
After analysis of the measured and planned profiles, consistently higher delivered doses were
seen for those planes taken through the region of interest representing the spinal cord. This was
particularly noteworthy as a dose exceeding the maximum limit to the spinal cord could lead to paralysis.
Further investigation was required to identify the reason for discrepancy between the planned and
measured dose at the spinal cord region of interest. Angular dependence was ruled out by individually
delivering the SSRS beams to the diode array and comparing the delivered dose to the calculations
performed by the treatment planning system. Consistently higher doses were measured when the beams
were at their prescribed gantry and collimator angles. Variable doses were measured when the beams
were overridden to be delivered at gantry and collimator angles of 0°. Once a millimeter shift was applied
to the data, presumably to account for gantry sag when the gantry is placed at 0°, the magnitude of the
percent difference between measured and calculated dose points decreased for most delivered beams.
The evaluation of the delivery of individual SSRS beams proved that the delivery system was capable of
delivering the planned beams when the gantry and collimator angles were set to 0°, which indicates that
the treatment planning system is possibly incapable of modeling the beam accurately for the combination
of the prescribed gantry and collimator angles as well as the optimized modulation required for the SSRS
plan.
To confirm the discrepancy between the measured and calculated dose, a different experimental
setup was adopted to repeat the measurements of the individual beams delivered to the diode array. Ion
chamber measurements were taken at the approximate position of the spinal cord, specifically its
perimeter proximal to the vertebral column and its center. Results confirmed the difference in the
measured and delivered dose at the level of the spinal cord for the SSRS plan in that doses delivered
were consistently higher for the prescribed gantry angles. The results from both the diode array and ion
chamber experiments suggest an inaccuracy in the treatment planning system as it was utilized for the
SSRS treatment plan.
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4.2 Limitations of Work
This work was limited by 1-mm resolution along one axis. This prevented the use of 2dimensional metrics, such as gamma analysis, in assessing the delivery accuracy of the treatment
systems. Additionally, artifacts were produced in the profiles due to over-responding diodes when
measured files were combined for the aggregate file. These artifacts created a “smearing” effect that was
a direct result of the dosimeter despite dose calibrations performed on the diode array before every
measurement session. Lastly, this project lacks complete sets of data for the SSRS treatment delivery at
2 and 2.7 cm posterior offsets along the patient superior-inferior axis.

4.3 Evaluation of Hypothesis
Based on the findings of this project, the Elekta Infinity and Versa HD delivery systems were
adequate for lung SBRT treatments but require further exploration for the commencement of spine SRS
treatments at Mary Bird Perkins Cancer Center. The hypothesis of this project was that the Elekta Infinity
and Versa HD linear accelerators would be sufficient for lung SBRT and spine SRS treatments as
deemed by clinical standards. While both treatment deliveries achieved 1-mm accuracy on average in
terms of positional alignment and isodose level coverage, the delivery of the SSRS treatment plan
resulted in a consistently higher delivered dose to the region of the spinal cord at the prescribed gantry
and collimator angles.

4.4 Future Work
The data in this research was obtained using a diode array with a novel setup allowing for 1-mm
resolution. With this research design, major dose discrepancies were found between the measured and
planned treatment plans. Further analysis with a different dosimeter confirmed these findings to be true
and not a result of experimental design. Therefore, these findings suggest an inconsistency between the
treatment planning system and the delivery system. Assessment of the treatment planning system as it
applies to high dose single fraction treatments could be evaluated further. Moreover, additional treatment
plans utilizing techniques other than 3D conformal and step and shoot IMRT could be tested on these
platforms using the novel design of this project.
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Appendix A. Profiles Comparing Measured and Calculated Treatment
Plans

Figure A.1. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the lung SBRT
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.2. Coronal left-right profile plots through Y = 1 cm of the lung SBRT treatment plan delivered on
the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head located
at the MBPCC Gonzales facility, respectively.
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Figure A.3. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the lung SBRT
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.4. Coronal left-right profile plots through Y = 0.5 cm of the lung SBRT treatment plan delivered
on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head
located at the MBPCC Gonzales facility, respectively.
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Figure A.5. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the lung SBRT
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.6. Coronal left-right profile plots through Y = 0 cm of the lung SBRT treatment plan delivered on
the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head located
at the MBPCC Gonzales facility, respectively.
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Figure A.7. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the lung SBRT
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.8. Coronal left-right profile plots through Y = -0.5 cm of the lung SBRT treatment plan delivered
on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head
located at the MBPCC Gonzales facility, respectively.
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Figure A.9. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the lung SBRT
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.10. Coronal left-right profile plots through Y = -1 cm of the lung SBRT treatment plan delivered
on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta Infinity with Agility head
located at the MBPCC Gonzales facility, respectively.
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Figure A.11. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 1 cm of the lung
SBRT treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.12. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0.5 cm of the lung
SBRT treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.13. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0 cm of the lung
SBRT treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.14. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -0.5 cm of the lung
SBRT treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.15. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -1 cm of the lung
SBRT treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.16. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the spine SRS
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.17. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the spine SRS
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.18. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the spine SRS
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.19. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the spine SRS
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.20. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the spine SRS
treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.21. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 1 cm of the spine
SRS treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.22. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0.5 cm of the spine
SRS treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.23. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = 0 cm of the spine
SRS treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.24. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -0.5 cm of the spine
SRS treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.25. Coronal superior-inferior profile plots of Trials 1 and 2 taken through X = -1 cm of the spine
SRS treatment plan delivered on the Elekta Infinity with Agility head at the MBPCC Baton Rouge facility.
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Figure A.27. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the spine SRS
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.28. Coronal left-right profile plots through Y = 0 cm of the spine SRS treatment plan shifted
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.29. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the spine SRS
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.30. Coronal left-right profile plots through Y = 1 cm of the spine SRS treatment plan shifted
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.31. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the spine SRS
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.32. Coronal left-right profile plots through Y = 0.5 cm of the spine SRS treatment plan shifted
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.33. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the spine SRS
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.34. Coronal left-right profile plots through Y = -0.5 cm of the spine SRS treatment plan shifted
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.

84

Figure A.35. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the spine SRS
treatment plan shifted posteriorly by 2 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.36. Coronal left-right profile plots through Y = - 1 cm of the spine SRS treatment plan shifted
posteriorly by 2 cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.37. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0 cm of the spine SRS
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.38. Coronal left-right profile plots through Y = 0 cm of the spine SRS treatment plan shifted
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.39. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 1 cm of the spine SRS
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.40. Coronal left-right profile plots through Y = 1 cm of the spine SRS treatment plan shifted
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.

90

Figure A.41. Coronal left-right profile plots of Trials 1 and 2 taken through Y = 0.5 cm of the spine SRS
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.42. Coronal left-right profile plots through Y = 0.5 cm of the spine SRS treatment plan shifted
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.43. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -0.5 cm of the spine SRS
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.44. Coronal left-right profile plots through Y = -0.5 cm of the spine SRS treatment plan shifted
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Figure A.45. Coronal left-right profile plots of Trials 1 and 2 taken through Y = -1 cm of the spine SRS
treatment plan shifted posteriorly by 2.7 cm with kV-CBCT positioning and delivered on the Elekta Infinity
with Agility head at the MBPCC Baton Rouge facility.
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Figure A.46. Coronal left-right profile plots through Y = -1 cm of the spine SRS treatment plan shifted
posteriorly by 2.7cm delivered on the Elekta Versa HD at the MBPCC Baton Rouge facility and the Elekta
Infinity with Agility head located at the MBPCC Gonzales facility, respectively.
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Appendix B. MV Isocenter Accuracy Test Data
The data was analyzed with the RIT Isocenter Analysis Tool. The green circle represents the
perimeter of the radiation field defined by the stereotactic cone with the green cross representing the
center of the cone. Additionally, the blue circle delineates the edge of the BB with the blue cross
representing the center of the BB. The maximum value of the first four numbers in the R (mm) deviation
column represents the MV isocenter radius for gantry rotation. The maximum value of the eight numbers
in the R (mm) column represents the radius of the MV isocenter on the gantry and the treatment table.

Figure B.1. MV Isocenter analysis of the Elekta Infinity platform with Agility head located at the Baton
Rouge MBPCC facility (Infinity 1). EPID mages were analyzed with the RIT Isocenter Analysis Tool for the
four cardinal gantry angles with couch at 0° and four couch angles with gantry at 0°.
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Figure B.2. MV Isocenter analysis of the Versa HD™ platform located at the Baton Rouge MBPCC facility
(Infinity 1). EPID mages were analyzed with the RIT Isocenter Analysis Tool for the four cardinal gantry
angles with couch at 0° and four couch angles with gantry at 0°.
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Figure B.3. MV Isocenter analysis of the Elekta Infinity platform with Agility head located at the Gonzales
MBPCC facility (Infinity 2). EPID mages were analyzed with the RIT Isocenter Analysis Tool for the four
cardinal gantry angles with couch at 0° and four couch angles with gantry at 0°.
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Appendix C. Data from kV-CBCT Translations
Table C.1 displays the coordinates for the initial alignment of the MapCHECK2 array to the room
lasers as well as the final suggested shifts provided by XVI after translation and kV-CBCT image
registration to confirm the desired position was achieved. Even though the kV-CBCT registration
algorithm is capable of identifying sub-millimeter shifts, the treatment table is only capable of millimeter
adjustments. Therefore, 1 mm shifts are deemed acceptable and are not required to be executed.
However, a tolerance of ±0.05 cm was set for the purpose of this study in accessing the accuracy of
delivery. The data in Table 3.3 shows that the applied posterior shifts were within the acceptable range
for data acquisition.
Table C.1. Data acquired from the XVI kV-CBCT image registration used for assessing the positioning of
the diode array before measurement sessions.
After Final kV-CBCT; Residual Shifts
Confirming Correct Translation

Initial Position
Measuremen
t Session
SSRS 2cm
Posterior
Shift, Trial 1
on Infinity 1
SSRS 2cm
Posterior
Shift, Trial 2
on Infinity 1
SSRS 2cm
Posterior
Shift on
Versa HD
SSRS 2cm
Posterior
Shift on
Infinity 2
SSRS 2.7cm
Posterior
Shift, Trial 1
on Infinity 1
SSRS 2.7cm
Posterior
Shift, Trial 2
on Infinity 1
SSRS 2.7cm
Posterior
Shift on
Versa HD

X-Lateral
(cm)

YLongitudinal
(cm)

ZVertical
(cm)

X-Lateral
(cm)

YLongitudinal
(cm)

Z-Vertical
(cm)

+0.03

+0.08

-0.04

+0.02

-0.03

-2.03

-0.08

-0.11

-0.05

+0.01

+0.00

-2.04

+0.05

+0.12

+0.08

-0.02

+0.03

-2.05

+0.02

+0.04

-0.05

+0.02

-0.05

-2.05

-0.05

-0.10

+0.05

+0.04

0.00

-2.73

+0.04

+0.09

-0.05

+0.03

0.00

-2.74

+0.06

+0.04

-0.02

+0.01

+0.03

-2.71

100

SSRS 2.7cm
Posterior
Shift on
Infinity 2

+0.02

-0.02

-0.09
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-0.03

-0.01

-2.74
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